YongHyun Han

Dr. YongHyun Han

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Science
Verified
Journal Article
Closed access
PDF file
YHYongHyun Han
YongHyun Han
EOEmily J. Onufer
Emily J. Onufer
LHLi-Hao Huang
Li-Hao Huang
RSRobert W. Sprung
Robert W. Sprung
WDW. Sean Davidson
W. Sean Davidson
GRGwendalyn J. Randolph
Gwendalyn J. Randolph
Intestinal HDL is hepatoprotective: High-density lipoprotein (HDL) is important for cholesterol metabolism and may have anti-inflammatory and antimicrobial properties. Although HDL is mainly produced by the liver, the intestine is also a source. Han et al. show in mice that intestinal HDL is not routed to the systemic circulation. Rather, in the form of HDL3, it is directly transported to the liver through the hepatic portal vein. There, it sequesters bacterial lipopolysaccharide from the gut that can trigger inflammation and liver damage. In various models of liver injury, loss of enteric HDL exacerbated pathology. By contrast, drugs elevating intestinal HDL improved disease outcomes. HDL3 is enriched in human portal venous blood, suggesting that enteric HDL may be targetable for the treatment of liver disease. Science , abe6729, this issue p. eabe6729

26 December 2024 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
NKNam-Hee Kim
Nam-Hee Kim
SSSo-Jin Sim
So-Jin Sim
HHHong-Gyu Han
Hong-Gyu Han
JYJeong-Hyuk Yoon
Jeong-Hyuk Yoon
YHYongHyun Han
YongHyun Han


22 January 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
MKMi-Yeon Kim
Mi-Yeon Kim
BJBirang Jeong
Birang Jeong
GLGeun-Shik Lee
Geun-Shik Lee
HJHongjun Jeon
Hongjun Jeon
YYYoon Mee Yang
Yoon Mee Yang
YHYongHyun Han
YongHyun Han

30 April 2022 in BMB Reports
Verified
Journal Article
Open access
PDF file
KLKyeong-Jin Lee
Kyeong-Jin Lee
MKMi-Yeon Kim
Mi-Yeon Kim
YHYongHyun Han
YongHyun Han
Kyeong-Jin Lee, Mi-Yeon Kim & Yong-Hyun Han. BMB Reports 2022;55:166-74. https://doi.org/10.5483/BMBRep.2022.55.4.022

15 April 2025 in Cell Reports Medicine
Verified
Journal Article
Open access
DKDong-Hyun Kim
Dong-Hyun Kim
GCGona Choi
Gona Choi
ESEun-Bi Song
Eun-Bi Song
HLHanna Lee
Hanna Lee
JKJaehui Kim
Jaehui Kim
YHYongHyun Han
YongHyun Han
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by inflammation and fibrosis, with enhanced interleukin-18 (IL-18) signaling. IL-18-binding protein (IL-18BP) neutralizes IL-18, but its therapeutic potential in MASH is unclear. We find elevated IL-18BP and IL-18 levels in patients with MASH and mice, with free IL-18 correlating with disease severity. IL-18 stimulates interferon-gamma (IFNγ) production in CD4 T cells, increasing hepatic IL-18BP. IL-18BP-deficient mice show worsened liver inflammation and fibrosis. We develop a human IL-18BP biologics (APB-R3) and inject it to mice to evaluate its pharmacologic efficacy. APB-R3 significantly improves MASH in reducing fibrosis and inflammation and inhibits hepatic stellate cell activation via the cGMP pathway. This study proposes that abrogation of IL-18 signaling by boosting IL-18BP can strongly inhibit the development of MASH-induced fibrosis, and our engineered IL-18BP biologics can become a promising therapeutic candidate for curing MASH.